• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
RCE
Click for more information
2.27% 43.0¢

RECCE PHARMACEUTICALS LTD - Announcements

Market Cap $118.1M  ! watchlist Created with Sketch. Add to my watchlist

Recce Pharmaceuticals Ltd is an Australia-based company engaged in the development and... Recce Pharmaceuticals Ltd is an Australia-based company engaged in the development and commercialization of a new class of synthetic anti-infectives designed to address the urgent global health problems of antibiotic-resistant superbugs and emerging viral pathogens. The Company's anti-infective pipeline includes three broad-spectrum, synthetic polymer anti-infectives: RECCE 327 as an intravenous and topical therapy that is being developed for the treatment of serious and potentially life-threatening infections due to Gram-positive and Gram-negative bacteria including their superbug forms; RECCE 435 as an orally administered therapy for bacterial infections; and RECCE 529 for viral infections. Through their multi-layered mechanisms of action, the Company's anti-infectives have the potential to overcome the hypercellular mutation of bacteria and viruses. All RECCE compounds are water soluble at all pH levels in their liquid form.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
RCE USA Patent Granted for Recce's AntibioticsPRICE SENSITIVE14/03/19
RCE Change of Director's Interest Notice07/03/19
RCE Half Yearly Report and AccountsPRICE SENSITIVE27/02/19
RCE Change in substantial holding15/02/19
RCE Change of Director's Interest Notice15/02/19
RCE Cleansing Statement15/02/19
RCE Notice under ASX Listing Rule 3.10.5A15/02/19
RCE Issue of Securities and Appendix 3B15/02/19
RCE Recce Successfully Raises $1.8 million via PlacementPRICE SENSITIVE08/02/19
RCE Trading HaltPRICE SENSITIVE06/02/19
RCE Appendix 4C and commentaryPRICE SENSITIVE31/01/19
RCE R&D Incentive Rebate ReceivedPRICE SENSITIVE31/01/19
RCE Funding UpdatePRICE SENSITIVE18/01/19
RCE Funding Update16/01/19
RCE Funding UpdatePRICE SENSITIVE18/12/18
RCE Company Constitution03/12/18
RCE Results of Meeting29/11/18
RCE Funding UpdatePRICE SENSITIVE23/11/18
RCE Investor Presentation21/11/18
RCE Appendix 4C and commentaryPRICE SENSITIVE01/11/18
RCE Notice of General Meeting/Proxy Form29/10/18
RCE Recce Meets Antibiotic Leaders to Explore Opportunities25/10/18
RCE Date of 2018 Annual General Meeting08/10/18
RCE R&D Incentive Rebate ReceivedPRICE SENSITIVE02/10/18
RCE Appendix 4G28/09/18
RCE 2018 Annual Report28/09/18
RCE Change of Registry Address: Automic P/L - Sydney Office28/09/18
RCE Funding UpdatePRICE SENSITIVE13/09/18
RCE Investor Presentation12/09/18
RCE Investor Presentation04/09/18
RCE Appendix 4E - Preliminary Final ReportPRICE SENSITIVE31/08/18
RCE Key Australian Patent for Recce's Broad-Spectrum AntibioticsPRICE SENSITIVE31/07/18
RCE Appendix 4C and commentaryPRICE SENSITIVE30/07/18
RCE Update on Progress of Broad Spectrum Antibiotic RECCE 327PRICE SENSITIVE17/07/18 download Created with Sketch. 180.48KB
RCE Change of Share Registry16/07/18 download Created with Sketch. 118.78KB
RCE Recce Presented at FNN/Shaw and Partners Investor Conference21/06/18 download Created with Sketch. 321.34KB
RCE Update on meeting with US FDAPRICE SENSITIVE05/06/18 download Created with Sketch. 520.35KB
RCE Investor Presentation05/06/18 download Created with Sketch. 2.3MB
RCE Recce Pharmaceuticals to Present at Investor Conference30/05/18 download Created with Sketch. 135.61KB
RCE Update on meeting with US FDA16/05/18
RCE Cleansing Statement01/05/18
RCE Appendix 3B01/05/18
RCE Appendix 4C and commentaryPRICE SENSITIVE30/04/18
RCE Initial Director's Interest Notice27/04/18
RCE Pharmaceutical Expert Joins Board of Directors24/04/18
RCE Additional AU$861,590 R&D Tax Incentive Rebate ReceivedPRICE SENSITIVE23/04/18
RCE RECCE Antibiotic International Media Attention19/04/18
RCE April Funding Update28/03/18
RCE Meeting with US FDA on Phase I Clinical Trial for RECCE 32708/03/18
RCE Recce Half Yearly Report and Appendix 4DPRICE SENSITIVE28/02/18
RCE Cleansing Statement16/02/18
RCE Appendix 3B16/02/18
RCE Results of Meeting16/02/18
RCE Data Submission & Further Communication Request with US FDAPRICE SENSITIVE15/02/18
RCE Investor Presentation31/01/18
RCE Appendix 4C and commentaryPRICE SENSITIVE31/01/18
RCE Recce to present at two investor conferences25/01/18
RCE Notice of General Meeting/Proxy Form17/01/18
RCE Cleansing Statement17/01/18
RCE Appendix 3B17/01/18
RCE Appendix 3B15/01/18
RCE AusIndustry Awards Recce Financial SupportPRICE SENSITIVE15/01/18
RCE Shares to be released from Escrow10/01/18
RCE Broker Presentation11/12/17
RCE Cleansing Statement04/12/17
RCE Appendix 3B04/12/17
RCE Company Secretary Appointment/Resignation29/11/17
RCE Results of Meeting21/11/17
RCE 2017 AGM Presentation21/11/17
RCE US FDA Grants Qualified Infectious Disease Product DesignatiPRICE SENSITIVE16/11/17
RCE Trading Halt Request14/11/17
RCE Trading HaltPRICE SENSITIVE14/11/17
RCE Change in Sydney Office Address08/11/17
RCE Cleansing Statement03/11/17
RCE Appendix 3B03/11/17
RCE Appendix 4C - quarterlyPRICE SENSITIVE31/10/17
RCE Change in substantial holding25/10/17
RCE Appendix 3B25/10/17
RCE Successful Share Purchase Plan23/10/17
RCE Notice of Annual General Meeting/Proxy Form20/10/17
RCE Appendix 4G20/10/17
RCE Annual Report to shareholders20/10/17
RCE Cleansing Statement03/10/17
RCE Appendix 3B03/10/17
RCE Recce Launches Share Purchase PlanPRICE SENSITIVE27/09/17
RCE Correction to Appendix 3B26/09/17
RCE Cleansing Statement25/09/17
RCE Appendix 3B25/09/17
RCE Response to ASX Price QueryPRICE SENSITIVE18/09/17
RCE Investor Presention15/09/17
RCE Cleansing Statement07/09/17
RCE Appendix 3B07/09/17
RCE Recce Confirms Pre-IND Data Submission to US FDAPRICE SENSITIVE07/09/17
RCE Appendix 4E and Financial ReportPRICE SENSITIVE01/09/17
RCE Appendix 4C - quarterlyPRICE SENSITIVE31/07/17
RCE Recce Confirms Delivery by Intravenous DripPRICE SENSITIVE31/07/17
RCE Cleansing Statement20/07/17
RCE Appendix 3B20/07/17
RCE Recce achieves milestone with volume productionPRICE SENSITIVE20/07/17
RCE Cleansing Statement22/06/17
RCE USA Patent Granted for Recce's Antibiotics
14/03/19PRICE SENSITIVE
RCE Change of Director's Interest Notice
07/03/19
RCE Half Yearly Report and Accounts
27/02/19PRICE SENSITIVE
RCE Change in substantial holding
15/02/19
RCE Change of Director's Interest Notice
15/02/19
RCE Cleansing Statement
15/02/19
RCE Notice under ASX Listing Rule 3.10.5A
15/02/19
RCE Issue of Securities and Appendix 3B
15/02/19
RCE Recce Successfully Raises $1.8 million via Placement
08/02/19PRICE SENSITIVE
RCE Trading Halt
06/02/19PRICE SENSITIVE
RCE Appendix 4C and commentary
31/01/19PRICE SENSITIVE
RCE R&D Incentive Rebate Received
31/01/19PRICE SENSITIVE
RCE Funding Update
18/01/19PRICE SENSITIVE
RCE Funding Update
16/01/19
RCE Funding Update
18/12/18PRICE SENSITIVE
RCE Company Constitution
03/12/18
RCE Results of Meeting
29/11/18
RCE Funding Update
23/11/18PRICE SENSITIVE
RCE Investor Presentation
21/11/18
RCE Appendix 4C and commentary
01/11/18PRICE SENSITIVE
RCE Notice of General Meeting/Proxy Form
29/10/18
RCE Recce Meets Antibiotic Leaders to Explore Opportunities
25/10/18
RCE Date of 2018 Annual General Meeting
08/10/18
RCE R&D Incentive Rebate Received
02/10/18PRICE SENSITIVE
RCE Appendix 4G
28/09/18
RCE 2018 Annual Report
28/09/18
RCE Change of Registry Address: Automic P/L - Sydney Office
28/09/18
RCE Funding Update
13/09/18PRICE SENSITIVE
RCE Investor Presentation
12/09/18
RCE Investor Presentation
04/09/18
RCE Appendix 4E - Preliminary Final Report
31/08/18PRICE SENSITIVE
RCE Key Australian Patent for Recce's Broad-Spectrum Antibiotics
31/07/18PRICE SENSITIVE
RCE Appendix 4C and commentary
30/07/18PRICE SENSITIVE
RCE Update on Progress of Broad Spectrum Antibiotic RECCE 327
17/07/18PRICE SENSITIVE download Created with Sketch. 180.48KB
RCE Change of Share Registry
16/07/18 download Created with Sketch. 118.78KB
RCE Recce Presented at FNN/Shaw and Partners Investor Conference
21/06/18 download Created with Sketch. 321.34KB
RCE Update on meeting with US FDA
05/06/18PRICE SENSITIVE download Created with Sketch. 520.35KB
RCE Investor Presentation
05/06/18 download Created with Sketch. 2.3MB
RCE Recce Pharmaceuticals to Present at Investor Conference
30/05/18 download Created with Sketch. 135.61KB
RCE Update on meeting with US FDA
16/05/18
RCE Cleansing Statement
01/05/18
RCE Appendix 3B
01/05/18
RCE Appendix 4C and commentary
30/04/18PRICE SENSITIVE
RCE Initial Director's Interest Notice
27/04/18
RCE Pharmaceutical Expert Joins Board of Directors
24/04/18
RCE Additional AU$861,590 R&D Tax Incentive Rebate Received
23/04/18PRICE SENSITIVE
RCE RECCE Antibiotic International Media Attention
19/04/18
RCE April Funding Update
28/03/18
RCE Meeting with US FDA on Phase I Clinical Trial for RECCE 327
08/03/18
RCE Recce Half Yearly Report and Appendix 4D
28/02/18PRICE SENSITIVE
RCE Cleansing Statement
16/02/18
RCE Appendix 3B
16/02/18
RCE Results of Meeting
16/02/18
RCE Data Submission & Further Communication Request with US FDA
15/02/18PRICE SENSITIVE
RCE Investor Presentation
31/01/18
RCE Appendix 4C and commentary
31/01/18PRICE SENSITIVE
RCE Recce to present at two investor conferences
25/01/18
RCE Notice of General Meeting/Proxy Form
17/01/18
RCE Cleansing Statement
17/01/18
RCE Appendix 3B
17/01/18
RCE Appendix 3B
15/01/18
RCE AusIndustry Awards Recce Financial Support
15/01/18PRICE SENSITIVE
RCE Shares to be released from Escrow
10/01/18
RCE Broker Presentation
11/12/17
RCE Cleansing Statement
04/12/17
RCE Appendix 3B
04/12/17
RCE Company Secretary Appointment/Resignation
29/11/17
RCE Results of Meeting
21/11/17
RCE 2017 AGM Presentation
21/11/17
RCE US FDA Grants Qualified Infectious Disease Product Designati
16/11/17PRICE SENSITIVE
RCE Trading Halt Request
14/11/17
RCE Trading Halt
14/11/17PRICE SENSITIVE
RCE Change in Sydney Office Address
08/11/17
RCE Cleansing Statement
03/11/17
RCE Appendix 3B
03/11/17
RCE Appendix 4C - quarterly
31/10/17PRICE SENSITIVE
RCE Change in substantial holding
25/10/17
RCE Appendix 3B
25/10/17
RCE Successful Share Purchase Plan
23/10/17
RCE Notice of Annual General Meeting/Proxy Form
20/10/17
RCE Appendix 4G
20/10/17
RCE Annual Report to shareholders
20/10/17
RCE Cleansing Statement
03/10/17
RCE Appendix 3B
03/10/17
RCE Recce Launches Share Purchase Plan
27/09/17PRICE SENSITIVE
RCE Correction to Appendix 3B
26/09/17
RCE Cleansing Statement
25/09/17
RCE Appendix 3B
25/09/17
RCE Response to ASX Price Query
18/09/17PRICE SENSITIVE
RCE Investor Presention
15/09/17
RCE Cleansing Statement
07/09/17
RCE Appendix 3B
07/09/17
RCE Recce Confirms Pre-IND Data Submission to US FDA
07/09/17PRICE SENSITIVE
RCE Appendix 4E and Financial Report
01/09/17PRICE SENSITIVE
RCE Appendix 4C - quarterly
31/07/17PRICE SENSITIVE
RCE Recce Confirms Delivery by Intravenous Drip
31/07/17PRICE SENSITIVE
RCE Cleansing Statement
20/07/17
RCE Appendix 3B
20/07/17
RCE Recce achieves milestone with volume production
20/07/17PRICE SENSITIVE
RCE Cleansing Statement
22/06/17
refresh Created with Sketch. REFRESH
 
(20min delay)
Last
43.0¢ 		Change
-0.010(2.27%) 		Mkt cap ! $118.1M
Open High Low Value Volume
44.0¢ 44.5¢ 43.0¢ $130.8K 297.2K

Buyers (Bids)

No. Vol. Price($)
4 31774 43.0¢
 

Sellers (Offers)

Price($) Vol. No.
44.0¢ 13243 1
View Market Depth
Last trade - 16.10pm 02/12/2024 (20 minute delay) ?
Last
44.0¢ 		  Change
-0.010 ( 1.12 %)
Open High Low Volume
44.0¢ 44.5¢ 44.0¢ 87918
Last updated 14.19pm 02/12/2024 ?
RCE (ASX) Chart

Top Stories

This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game

Today, one small pill holds the potential to transform cognitive medicine by addressing conditions like depression and Alzheimer’s. 
Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects Pan Asia Metals has scored $35 million from a New York private equity firm at the same time as the company's big rebrand push begins.
MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up Who the MinRes Board has decided to move on faster may or may not be amusing, depending on how much you've lost.
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025 Samples among the highest-ever-graded uranium soil samples recorded in mineral exploration history, and an imminent drill run.
Breaking news: New opportunities for investors & companies - HotCopper opens to capital raising! Companies can now raise capital through HotCopper! It’s a development allowing a highly cost-effective service to ASX-listed companies, while opening new investment opportunities to investors.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.